Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR6013549

— · cohortSQ2

693e0b79-5580-5619-a7cd-aa4d3cbe79c2

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortSQ2
subtype
cohortSQ2

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.590
  • E2F_TARGETS+0.560
  • G2M_CHECKPOINT+0.530
  • OXIDATIVE_PHOSPHORYLATION+0.500
  • MYC_TARGETS_V1+0.480
  • MTORC1_SIGNALING+0.390
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.280
  • APICAL_SURFACE+0.270
  • DNA_REPAIR+0.260
  • FATTY_ACID_METABOLISM+0.260

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
  • ANGIOGENESIS-0.410
  • IL6_JAK_STAT3_SIGNALING-0.400
  • TGF_BETA_SIGNALING-0.390
  • COMPLEMENT-0.380
  • KRAS_SIGNALING_UP-0.380
  • INFLAMMATORY_RESPONSE-0.360
  • INTERFERON_ALPHA_RESPONSE-0.350
  • INTERFERON_GAMMA_RESPONSE-0.350
  • ALLOGRAFT_REJECTION-0.340

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-A8-A079-01A-21R-A00Z-07
breast-umap@18
—B0.939
2TCGA-77-8143-01A-11R-2247-07
lung-landscapes@6
—cohortSQ10.928
3TCGA-33-4532-01A-01R-1201-07
lung-landscapes@6
—cohortSQ20.926
4SRR10900551
melanoma-umap@29
——0.915
5TCGA-85-8354-01A-31R-2326-07
lung-landscapes@6
—cohortSQ20.910
6TCGA-CN-A6V7-01A-12R-A34R-07
head-neck@1
——0.909
7AUR-AFUM-TTM1-A-1-1-R-A743-41
breast-umap@18
—E0.906
8TCGA-56-8304-01A-11R-2326-07
lung-landscapes@6
—cohortSQ10.905
9TCGA-63-A5MU-01A-11R-A26W-07
lung-landscapes@6
—cohortSQ20.897
10TCGA-63-A5MY-01A-11R-A26W-07
lung-landscapes@6
—cohortSQ20.895

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.590Idelalisib— uncovered
E2F_TARGETS0.560Inavolisib— uncovered
G2M_CHECKPOINT0.530Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.500Remibrutinib— uncovered
MYC_TARGETS_V10.480Inavolisib— uncovered
MTORC1_SIGNALING0.390Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.280Inavolisib— uncovered
APICAL_SURFACE0.270Temsirolimus— uncovered
DNA_REPAIR0.260Idelalisib— uncovered
FATTY_ACID_METABOLISM0.260Inavolisib— uncovered
GLYCOLYSIS0.250Inavolisib— uncovered
SPERMATOGENESIS0.220Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.180Idelalisib— uncovered
PEROXISOME0.180Idelalisib— uncovered
ADIPOGENESIS0.170Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.120Idelalisib— uncovered
MITOTIC_SPINDLE0.110Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.110Inavolisib— uncovered
P53_PATHWAY0.070Idelalisib— uncovered
KRAS_SIGNALING_DN0.060Remibrutinib— uncovered